Omura T. Forty years of cytochrome P450. Biochem Biophys Commun 1999; 266: 690–698.

Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999; 369: 1–10.

Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mu- cosa of rats and man. J Clin Invest 1987; 80: 1029–1036.

Domanski TL, Finta C, Halpert JR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386–392.

Lewis DF, Eddershaw PJ, Goldfarb PS, et al. Molecular modeling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 1996; 26: 1067–1086.

Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzyme involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–423.

Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247–259.

Paine MF, Khalighi M, Fishe JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552–1562.

Benet LZ, Kroetz DL, Sheiner LB. The dynamics of drug absorption, distribution, and elimination. Goodman & Gilman’s The Phamacological Basis of Therapeutics. Hardman JG, Lim-bird LE, Molimoff PB. eds. 9th ed. New York: McGraw-Hill, 2000: 3–28.

Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14–24.

Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–1490.

Carolyn L Cummins, Laurent Salphati, Michael J Reid, et al.In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Experi Ther 2003; 305 (l): 306–314.

Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999; 39: 361–398.

Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–1234.

Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidominetics. J Pharm Sci 1998; 87: 1322–1330.

Carolyn LC. Examining the interactive nature of cytochrome P450 3A4 and P-glycoprotein in intestinal drug metabolism. Dissert Abstr Int 2002; 63 (4): 1855.

Paavo Honkakoski, Masahiko Negishi. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347: 321–337.

Diao YY, He P, Wu MC, et al. The inducing effect of glycyrrhizin on itself in mice. J Chin Materia Medica 1999, 24 (9): 564–565.

Cheng JF, Teng SB, Chen DH, et al. Effect of glycyrrhizin and phenobarbital pretreatment of hepatic P450 3A enzyme in mice. J Fourth Milt Med Univ 2000, 21 (8): 968–971.

Wang Z, Kurosaki Y, Nakayama T, et al. Mechanism of gas-trointestinal absorption of glycyrrhizin in rats. Biol Pharm Bull 1994; 17 (10): 1399–1403.

Wu XC, Li Q, Xin HW, et al. The pharmacokinetics of enhancement of cyclosporin A by berberine chloride co-administrated in renal transplanted recipients. Asian J Drug Metab Pharmacokinet 2001, 1 (4): 257–261.

Xin HW, Wu XC, Li Q, et al. Effects of berberine chloride and co-administration with cyclosporin on CYP3A1 in rat liver and small intestine. Chin J Clin Pharmacol Ther 2004, 9 (5): 564–568.

Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31 (7): 47–64.

Sigusch H, Henschel L, Kraul H, et al. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994, 49: 675–679.

Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion-pharmacokinetic and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139–145.

Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–28.

Offman EM, Freeman DJ, Dresser GK, et al. Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70 (1): 17–23.

Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62: 135–142.

F Peter Guengerich. Cytochrome P450 enzymes in the generation of commercial products. Nature Rev Drug Disc 2002; 1 (5): 359–366.